Day: September 23, 2020

IRVINE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX) a global provider of Software as a Service (SaaS), engineering services and hardware for Edge Computing, the Internet of Things (IoT) and Remote Environment Management (REM), today announced its new Open-Q™ 865XR System on Module (SOM) solution for IoT applications. With the Open-Q 865XR SOM, Lantronix is leading the way to next-gen intelligent Augmented Reality/Virtual Reality (AR/VR) applications in AI machine learning, medical, gaming, logistics and retail sectors.“Our new Open-Q 865XR SOM gives product developers AR/VR capability at the edge, powerful general processing capability and professional-quality imaging needed to kickstart IoT application development,” said Jonathan Shipman, VP of Strategy at Lantronix Inc.Lantronix’s Open-Q 865XR SOM is...

LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces their supply agreement with Thermo Fisher Scientific Inc. (“Thermo Fisher”).This agreement secures dedicated production capacity and resources for Freeline from 2021 to 2027, inclusive. This will provide capacity for the planned Phase 2b/3 pivotal clinical trial and potential commercialisation of Freeline’s haemophilia B program, FLT180a, using the Company’s proprietary manufacturing platform and processes.Freeline has established the manufacturing process for FLT180a at Thermo Fisher’s Cambridge...

CAMBRIDGE, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 8,333,334 of its ordinary shares at a price to the public of $12.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 of its ordinary shares on the same terms and conditions. The...

BEIJING, Sept. 23, 2020 (GLOBE NEWSWIRE) — 36Kr Holdings Inc. (“36Kr” or the “Company”) (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced a business collaboration agreement (the “Agreement”) with Youku Tudou Inc. (“Youku”), a leading online long-form video platform in China and a key distribution platform for digital media and entertainment content under Alibaba Group (“Alibaba”). The collaboration with Youku will help further expand the Company’s content ecosystem and accelerate the commercialization of its content productions.Pursuant to the Agreement, 36Kr and Youku will jointly develop pan-commercial themed video programs to enrich the Company’s content ecosystem and attract more renowned content creators in the commercial vertical. The integration...

COLUMBUS, Ohio, Sept. 23, 2020 (GLOBE NEWSWIRE) — Worthington Industries, Inc. (NYSE: WOR) today reported net sales of $702.9 million and net earnings of $616.7 million, or $11.22 per diluted share, for its fiscal 2021 first quarter ended August 31, 2020. In the first quarter of fiscal 2020, the Company reported net sales of $855.9 million and a net loss of $4.8 million, or $(0.09) per diluted share. Results in both the current and prior year quarter were impacted by several unique items, as summarized below, including a net pre-tax gain of $746.6 million, or $10.74 per diluted share, in the current quarter related to the Company’s investment in Nikola Corporation (“Nikola”). See Recent Developments below for further information regarding the Company’s investment in Nikola.(U.S. dollars in millions, except per share amounts)In addition,...

LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its intranasal SARS-CoV-2 vaccine prototype for COVID-19, using BC-PIV technology, successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen (Ag) of SARS-CoV-2 in mice. A mouse model study was conducted to assess systemic IgG and mucosal IgA antibody production against S1 Ag after intranasal vaccination with MediciNova’s BC-PIV SARS-CoV-2 vaccine prototype. We confirmed a high IgA antibody titer against S1 Ag in the nasal lavage fluid from mice given intranasal BC-PIV SARS-CoV-2 vaccine. We also confirmed that a high IgG antibody titer against S1 Ag...

VANCOUVER, Wash., Sept. 23, 2020 (GLOBE NEWSWIRE) — ORCHID VENTURES, INC. (CSE: ORCD OTC: ORVRF) (the “Company” or “Orchid”), a multi-state cannabis innovation company, is pleased to announce that it is launching three new product lines in California and Oregon.The Orchid Brands team has been hard at work developing three news lines of vape products as the company has seen a complete rebound in vape sales since the vape scare of 2019. These products have been developed and will be positioned to appeal to different consumer segments. Firstly, there is Orchid Vibes, a value-priced product featuring a newly developed PurTec Summit cartridge and introducing more contemporary terpene profiles like Mimosa and Purple Punch. The company has also improved the Orchid Classic line up, which are mid-tier products featuring their classic Orchid...

RENO, Nev., Sept. 23, 2020 (GLOBE NEWSWIRE) — NuLegacy Gold Corporation is pleased to report that it has received final approval from the Bureau of Land Management (“BLM”) of a modified Plan of Operations (“POP”) on its 100% controlled Red Hill gold project in the Carlin gold-trend of Nevada. With this permit approval, the planned Phase One exploration drill program of the highly prospective Rift Anticline target can commence.NuLegacy has identified three high-priority drill targets in the northern half of the Rift Anticline and three additional targets extending south along a north northwest-oriented corridor measuring 5.5 km long and up to 1.2 km wide.The Rift Anticline is a buried ridge of Paleozoic sedimentary rocks considered favourable for discovery of Carlin style gold mineralization. Detailed drill plans have been developed...

BOLTON, Ontario, Sept. 23, 2020 (GLOBE NEWSWIRE) — Titanium Transportation Group Inc. (“Titanium” or the “Company”) (TSX VENTURE:TTR), a leading provider of transportation and logistics services throughout North America, is pleased to announce that all of the nominees listed in the Company’s Management Information Circular for the Annual and Special Meeting of Shareholders held on September 22, 2020 (the “Meeting”) were elected to the Board of Directors. Each director will serve until the next annual meeting of shareholders or until their successors are elected or appointed or they otherwise cease to serve as directors.Detailed results of the vote for the election of directors held at the meeting are set out below:A total of 23,011,030 shares were voted at the Meeting, representing 62.98%...

First orally available integrin inhibitor from MInT Platform to enter the clinicMORF-057, inhibitor of α4β7integrin, in development to treat inflammatory bowel diseasePhase 1 program to assess safety and pharmacokinetics of MORF-057 as well as α4β7receptor occupancy as a clinically relevant biomarkerWALTHAM, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) — Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the first healthy volunteers have received MORF-057 in a phase 1 clinical trial designed to evaluate MORF-057’s safety and pharmacokinetic profile in addition to predictive pharmacodynamic signals. MORF-057 is in clinical development as an oral small molecule inhibitor of the α4β7 integrin for the treatment...